Shristi Butta1, Manoj Kumar Gupta2. 1. Department Pathology, NRS Medical College, Kolkata, West Bengal, India. 2. Department Tropical Medicine, Medical College, Kolkata, West Bengal, India.
Abstract
INTRODUCTION: MGMT (O-6-methylguanine-DNA methyl transferase) is a DNA repair enzyme with implications on chemoresistance and subsequent patient prognosis. This study investigated the association of MGMT with the various grades and subtypes of gliomas and evaluated the associated clinical outcome of these patients. METHODS: This observational longitudinal follow up study spun over a period of 36 months and included 33 patients with primary glioma who underwent surgical interventions and chemoradiotherapy at a tertiary care center in Kolkata. The surgical samples were processed and histopathologically typed. Immunohistochemical analysis was done using anti-MGMT antibody and MGMT status was determined. Patients were followed up for 3 years. RESULTS: Males were 1.3 times more commonly affected by gliomas. Mean age was 42.9 years for females and 47.2 years for males. Frontal lobe was the most commonly involved site whereas focal neurological deficit was the most common symptom. Karnofsky performance score was higher for low grade gliomas and lower for high grade gliomas (p=0.04). Significant association was found between histopathological grade and MGMT immunoexpression (p=0.0001) as well as histopathological subtype and MGMT status (p=0.0036). On follow up, mean survival of the patients was 25.4 months. Significant association was found between MGMT status and survival of the patients (p=0.0437). CONCLUSION: MGMT immunoexpression is significantly associated with different grades and subtypes of gliomas. In addition, MGMT has significant implications on chemoresistance and patient survival. Hence, MGMT expression should be mandatorily checked before starting the chemotherapy.
INTRODUCTION: MGMT (O-6-methylguanine-DNA methyl transferase) is a DNA repair enzyme with implications on chemoresistance and subsequent patient prognosis. This study investigated the association of MGMT with the various grades and subtypes of gliomas and evaluated the associated clinical outcome of these patients. METHODS: This observational longitudinal follow up study spun over a period of 36 months and included 33 patients with primary glioma who underwent surgical interventions and chemoradiotherapy at a tertiary care center in Kolkata. The surgical samples were processed and histopathologically typed. Immunohistochemical analysis was done using anti-MGMT antibody and MGMT status was determined. Patients were followed up for 3 years. RESULTS: Males were 1.3 times more commonly affected by gliomas. Mean age was 42.9 years for females and 47.2 years for males. Frontal lobe was the most commonly involved site whereas focal neurological deficit was the most common symptom. Karnofsky performance score was higher for low grade gliomas and lower for high grade gliomas (p=0.04). Significant association was found between histopathological grade and MGMT immunoexpression (p=0.0001) as well as histopathological subtype and MGMT status (p=0.0036). On follow up, mean survival of the patients was 25.4 months. Significant association was found between MGMT status and survival of the patients (p=0.0437). CONCLUSION: MGMT immunoexpression is significantly associated with different grades and subtypes of gliomas. In addition, MGMT has significant implications on chemoresistance and patient survival. Hence, MGMT expression should be mandatorily checked before starting the chemotherapy.
Authors: Michael Weller; Jörg Felsberg; Christian Hartmann; Hilmar Berger; Joachim P Steinbach; Johannes Schramm; Manfred Westphal; Gabriele Schackert; Matthias Simon; Jörg C Tonn; Oliver Heese; Dietmar Krex; Guido Nikkhah; Torsten Pietsch; Otmar Wiestler; Guido Reifenberger; Andreas von Deimling; Markus Loeffler Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Fausto J Rodriguez; Stephen N Thibodeau; Robert B Jenkins; Karen V Schowalter; Bolette L Caron; Brian P O'neill; Charles David James; Charles David James; Sandra Passe; Jeff Slezak; Caterina Giannini Journal: Appl Immunohistochem Mol Morphol Date: 2008-01
Authors: Margriet IJzerman-Korevaar; Tom J Snijders; Alexander de Graeff; Saskia C C M Teunissen; Filip Y F de Vos Journal: J Neurooncol Date: 2018-10-30 Impact factor: 4.130
Authors: Yong Sun; Zhen Dong Liu; Run Ze Liu; Xiao Yu Lian; Xing Bo Cheng; Yu Long Jia; Bin Feng Liu; Yan Zheng Gao; Xinjun Wang Journal: Mol Biol Rep Date: 2022-06-16 Impact factor: 2.742